DOCSLIB.ORG

Hydrochlorothiazide & Hydroflumethiazide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hydrochlorothiazide & Hydroflumethiazide Postgrad Med J: first published as 10.1136/pgmj.36.416.392 on 1 June 1960. Downloaded from 392 THERAPEUTIC SYMPOSIA-2: NEW DIURETICS HYDROCHLOROTHIAZIDE & HYDROFLUMETHIAZIDE JOAN F., ZILVA, B.Sc., M.D., M.R.C.P. Department of C1h4mical Pathology, Westminster Hospital Medical School, S.W. I Pitts2O has defined a diuretic as an agent which In 1958 de Stevens et al.3 synthesized dihydro- promotes urinary excretion of sodium and chloride chlorothiazide which only differed from chloro- or bicarbonate with secondary loss of water. thiazide in having the double. bond in the 3: 4 These ions are, as he points out, the major ones position saturated with two hydrogen atoms, and in the extra-cellular fluid, and it may be added following a pattern now familiar in other fields, that the ideal diuretic would result in excretion of a further attempt was made to alter the action of urine (over and above the base line levels) of the drug by substituting a trifluoromethyl group composition as near as possible to that of this for the chlorine atom in position 6 of the hydro- fluid. Rees24 has called this the ' ideal diuretic chlorothiazide molecule. fluid '. Preliminary trials on animals3 suggested that Since Vogl first noted that a syphilitic patient these new derivatives had less inhibitory effect on copyright. treated with organic mercurials experienced a carbonic anhydrase than the parent substance, diuresis, diuretics of this type have been widely and therefore that both potassium and bicarbonate used with great success. However, the poor loss were reduced. It was hoped that the problem absorption and the irritant effect of this group of of hypokalaemia encountered so often in the use substances on the gastrointestinal tract necessitate of chlorothiazide would be overcome. However, the expense and discomfort of parenteral ad- as will be shown, these hopes have not been ministration. For some years attempts were made realised. There is apparently no difference in to find a potent oral diuretic, but most of these, practice between hydrochlorothiazide and hydro- http://pmj.bmj.com/ such as the pure carbonic anhydrase inhibitors, flumethiazide and they will therefore be discussed had serious disadvantages. However, in 1957 together. Novello and Sprague'9 synthesised chlorothiazide (6-chloro-7-sulphamyl-I, 2, 4-benzothiadiazine-I, i-dioxide), which, in spite of its sulphonamido Mode of Action (-SO2NH2) group seemed to have only a mild As has been stated above, by virtue of its inhibitory effect on carbonic anhydrase. By far -SO2NH2 group chlorothiazide has some inhibitory its most potent action seemed to be an inhibition effect on carbonic anhydrase. This enzyme cata- on September 29, 2021 by guest. Protected of sodium and chloride reabsorption in the renal lyses the reaction. tubules similar to that of the mercurials. How- CO2 + H20 = H2C03 ever, as might be expected, the presence of the in the renal tubule. Ionisation of H2CO3 to H + icarb6nic anhydrase inhibitory effect does result in and HCO-3 makes available hydrogen ions for greater loss of potassium than with mercurials exchange with cations such as sodium and potas- (though this is much less than with the pure sium in the glomerular filtrate, and reabsorption carbonic anhydrase inhibitors such as acetazol- of NaHCO3 and KHCO3 results. If the enzyme amide). Clinical trials repeatedly demonstrated is inhibited, potassium and bicarbonate as well as that while chlorothiazide was the most satisfactory sodium will be lost in the urine. This occurs to and safest oral diuretic so far discovered; yet there a large extent with acetazolamide, and much less was a real danger of potassium depletion, especially so with chlorothiazide. With hydrochlorothiazide in cases with severe secondary aldosteronism such and hydroflumethiazide this action is still less, but as advanced congestive cardiac failure or hepatic' bicarbonate loss is diminished much more than cirrhosis, or those on strict sodium restric- that of potassium. Therefore, the effect of the tion.', 16,23,26,27 chlorothiazide group on excretion of this cation Postgrad Med J: first published as 10.1136/pgmj.36.416.392 on 1 June 1960. Downloaded from June 1960 ZILVA: Hydrochlorothiazide and Hydroflumethiazide 393 Ctg c ti ()( CE3:x 0i- 03- Chlorothiazide Hydrochlorothiazide Hydrof2lumethiazide cannot' wholly be due to inhibition of carbonic choose between chlorothiazide on the one hand,. anhydrase. and hydrochlorothiazide and hydroflumethiazide The'Ts mercurial-.like effect of chlorothia'zide and on the other, if differences in potency are allowed its derivatives on the''reabsorption of sodium and for.88 2, 6, 7, 13,15 Water excretion is secondary chloride has.not been elucidated. Pitts2o points to loss of these ions. out that its action and that of the mercurials is -- However, the 'ideal.' diuretic results in an additive, and that they may, therefore, act at increased urinary loss of electrolytes in proportion different parts *of the tubule, or on different to their concentrations in the extra-cellular fluid mechanisms at the same part. Labelled hydro- that is, the ratio of Na Cl: HCO' in the urine chlorothiiazid has been shown to collect in the should be approximately 140 : 100: 30. Any drug distal' 1f'rt 6f -th proximal -con.yoluted' ul;s.4 which alters these ratios will tend to. cause a disturbance of acid-base balance. Thus acetazol- Potency, Dosage and Duration of 4Action amide, by increasing the excretion of bicarbonate Aft w.orkers agree that weigl'kt for weight hydro- in proportions greater than those given above, chlorothiazide and hydroflumethiazide'are Io to frequently causes a 'hyperchloraemic acidosis, 20 times as potel fas"chlorothizidde. 3,2, 5, 7, 8;i, 21 while the use of mercurials, which results in very This in-itself is of no-great advawege-since chioro- little bicarbonate excretion may lead to hypo- copyright. thiazide is of an adequate potency. The fact that chloraemic alkalosis; both of these conditions are the p'atient is obliged to swallow a smaller tablet is associated with the development,.of resistance to not, in itself, a worthwhile outcome of the amount the drug. Chlorothiazide, by virtue of its mild of research done on the subject. It has been carbonic anhydrase inhibitory effect causes more claimed that hydrochlorothiazide and hydro- loss of bicarbonate. than the- mercurials, and flumethiazide have a more prolonged action than although the ratio of sodium to- chloride is about chlorothiazide,6' 28 and this might be an advan- I to i; trials'have shown little or no tendency to tage. However, this effect seems 'to Us to be acid-base disturbances. However, both its derivra- http://pmj.bmj.com/ variable.. Individual -differences between-subjects tives under consideration here have little effect on make this sqrt of difference difficult to assess. bicarbonate excretion, and both sodium and The greater potency of hydrochlorothiazide and potassium are lost mainly in the form of chloride. hydroflumethiazide is almost certainily associated It has repeatedly been observed that with these with the fact that a larger percentage of a -given two. drugs more chloride than sodium is ex- dose appears in.the urine than with chlorothia- creted,, I6s'13, 29 and as might be-predicted: there zide.28 This may be due to more efficient absorp- have been reports of the development of hypo- tion from the--intestine, or perhaps to the fact that chloraerwa.21, It may be that this will prove on September 29, 2021 by guest. Protected while chlorothiazide is excreted in the bile, its to be a drawback of long continued use of hydro- derivatives are not, and thus more is available for chlorothiazide and hydroflumethiazide. renal excretion.7 Dose-response curves8' 13, 17 seem to show that Potassium while there is an increasing diuretic response.with As has been stated above, hypokalaemia is the up to 50 or i00 mg. of the drug, no advantage is greatest hazard of chlorothiazide therapy, and-it to be gained from administration of larger doses. was hoped that the risk might be less with-its,, derivatives. However, this has not proved to. be Renal Loss of Electrolytes , 11,21,29 and potassium supplements should Sodium, Chloride and Bicarbonate be 'given with these drugs. The greatest loss of The efficiency of a diuretic is judged by its potassium occurs in patients with marked second- ability to increase the excretion of sodium and ary hyperaldosteronism, particularly those with chloride by the kidneys, and using this criterion, hepatic cirrhosis, in which the drug may precipi- there is no doubt that all the chlorothiazide group tate hepatic coma, possibly as a secondary result are very effective. In this respect there is little to of hypokalaemia.23 15 Potassium loss is also aggra- Postgrad Med J: first published as 10.1136/pgmj.36.416.392 on 1 June 1960. Downloaded from 304 POSTGRADUATE MEDICAL JOURNAL Yune I960 vated in subjects on strict sodium restriction, effects. The more serious complications of since less sodium is then available to balance the agranulocytosis and thrombocytopenic purpura excretion of chloride and the deficit is largely have also been reported with chlorothiazide,30 18 made up of potassium. but these are very rare, and have not yet been For these reasons, patients treated with the reported with the analogues. chlorothiazide analogues should receive potassium supplements, probably on the days between the Summary doses of the diuretic,22 and should be allowed salt in their diet. In addition, care should be taken Hydrochlorothiazide and hydroflumethiazide with digitalis therapy, since sensitivity to this drug are relatively safe oral diuretics. is increased by potassium depletion.29 Weight for weight, they are more potent than In passing it may be noted that some potassium chlorothiazide. loss occurs with mercurials, but that the much Compared with the latter, the tendency to lower incidence of hypokalaemia in patients treated produce urinary potassium loss is not significantly with them may be due to the fact that these reduced.
Load more

Recommended publications
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 10, October 1995 DIURETICS IN CHILDREN • Overview • Loop Diuretics • Thiazide Diuretics • Metolazone • Potassium Sparing Diuretics • Diuretic Dosages • Efficacy of Diuretics in Chronic Pulmonary Disease • Summary • References Pharmacology Literature Reviews • Ibuprofen Overdosage • Predicting Creatinine Clearance Formulary Update Diuretics are used for a wide variety of conditions in infancy and childhood, including the management of pulmonary diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD)(1 -5). Both RDS and BPD are often associated with underlying pulmonary edema and clinical improvement has been documented with diuretic use.6 Diuretics also play a major role in the management of congestive heart failure (CHF), which is frequently the result of congenital heart disease (7). Other indications, include hypertension due to the presence of cardiac or renal dysfunction. Hypertension in children is often resistant to therapy, requiring the use of multidrug regimens for optimal blood pressure control (8). Control of fluid and electrolyte status in the pediatric population remains a therapeutic challenge due to the profound effects of age and development on renal function. Although diuretics have been used extensively in infants and children, few controlled studies have been conducted to define the pharmacokinetics and pharmacodynamics of diuretics in this population. Nonetheless, diuretic therapy has become an important part of the management of critically ill infants and children. This issue will review the mechanisms of action, monitoring parameters, and indications for use of diuretics in the pediatric population (1-5). Loop Diuretics Loop diuretics are the most potent of the available diuretics (4).
    [Show full text]
  • Comprehensive Screening of Diuretics in Human Urine Using Liquid Chromatography Tandem Mass Spectrometry
    id5246609 pdfMachine by Broadgun Software - a great PDF writer! - a great PDF creator! - http://www.pdfmachine.com http://www.broadgun.com AAnnaallyyttiiccaaISllS N : 0974-7419 Volume 13 Issue 7 CCHHEEAnMM IndIIiSaSnT TJoRuRrnYaYl Full Paper ACAIJ, 13(7) 2013 [270-283] Comprehensive screening of diuretics in human urine using liquid chromatography tandem mass spectrometry Shobha Ahi1, Alka Beotra1*, G.B.K.S.Prasad2 1National Dope Testing Laboratory, Ministry of Youth Affairs and Sports, CGO Complex, Lodhi Road, New Delhi,-110003, (INDIA) 2SOS in Biochemistry, Jiwaji University, Gwalior, (INDIA) E-mail : [email protected] ABSTRACT KEYWORDS Diuretics are drugs that increase the rate of urine flow and sodium excretion Doping, diuretics; to adjust the volume and composition of body fluids. There are several LC-MS/MS; WADA; major categories of this drug class and the compounds vary greatly in Drugs of abuse. structure, physicochemical properties, effects on urinary composition and renal haemodynamics, and site mechanism of action. Diuretics are often abused by athletes to excrete water for rapid weight loss and to mask the presence of other banned substances. Because of their abuse by athletes, ’s (WADA) diuretics have been included in the World Anti-Doping Agency list of prohibited substances. The diuretics are routinely screened by anti- doping laboratories as the use of diuretics is banned both in-competition and out-of-competition. This work provides an improved, fast and selective –tandem mass spectrometric (LC/MS/MS) method liquid chromatography for the screening of 22 diuretics and probenecid in human urine. The samples preparation was performed by liquid-liquid extraction. The limit of detection (LOD) for all substances was between 10-20 ng/ml or better.
    [Show full text]
  • New Prohibited Substances Addition to Procedures Using Triple Quadrupole LC/MS2 Technique
    Poster MANFRED DONIKE WORKSHOP Pop V, Bican G, Pop A, Lamor M, Zorio M New prohibited substances addition to procedures using triple quadrupole LC/MS2 technique Romanian Doping Control Laboratory, Bucharest, ROMANIA Abstract New substances are added each year to the different classes of substances of WADA’s Prohibited List and have to be included in the test menu of each accredited doping control laboratory. For the analysis of some of these compounds the technique of choice is the LC/MS2 technique. Furthermore, with the decrease of MRPL levels, for stimulants from 500 ng/mL to 100 ng/mL and for narcotics from 200 ng/mL to 50 ng/mL, beginning from the entering in force on 1 January 2013 of the new WADA Technical Document TD2013MRPL, some of the compounds analyzed by the current GC/MS based procedure for stimulants and narcotics needed to be transferred to the LC/MS2 based procedure in order to lower their limit of detection. This paper-work presents the optimal conditions for preparation, separation and identification of new substances introduced to the LC/MS2 technique based procedures during the year 2012. Introduction Liquid chromatography coupled with mass spectrometry is increasingly used in doping control laboratories [1]. The current work presents the optimization of the LC/MS2 detection parameters and the introduction of the prohibited substances in the existent procedures, depending on the characteristics of the studied compounds. The studied compounds are benzthiazide, cyclopenthiazide, cyclothiazide, epitizide, hydroflumethiazide and polythiazide (thiazide diuretic compounds), tramadol and its O-desmethyl metabolite (narcotic compound from the monitoring program [2]), cyclazodone, pentetrazole, prolintane, propylhexedrine and selegiline (stimulants transferred from the GC/MS- to the LC/MS2-based procedure due to the decreasing of the MRPL levels for stimulants and narcotics [3]).
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Extracts from PRAC Recommendations on Signals Adopted at the 9-12 March 2020 PRAC
    6 April 20201 EMA/PRAC/111218/2020 Corr2,3 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording – Extracts from PRAC recommendations on signals Adopted at the 9-12 March 2020 PRAC The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through. 1. Immune check point inhibitors: atezolizumab; cemiplimab; durvalumab – Tuberculosis (EPITT no 19464) IMFINZI (durvalumab) Summary of product characteristics 4.4. Special warnings and precautions for use Immune-mediated pneumonitis [..] Patients with sSuspected pneumonitis should be evaluated confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2. LIBTAYO (cemiplimab) Summary of product characteristics 1 Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals. 2 A footnote was deleted on 8 April 2020 for the signal on thiazide and thiazide-like diuretics (see page 3). 3 A minor edit was implemented in the product information of the signal on thiazide and thiazide-like diuretics on 5 June 2020 (see page 4). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Spironolactone Therapy in Infants with Congestive Heart Failure Secondary to Congenital Heart Disease
    Arch Dis Child: first published as 10.1136/adc.56.12.934 on 1 December 1981. Downloaded from Archives of Disease in Childhood, 1981, 56, 934-938 Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease SUSAN M HOBBINS, RODNEY S FOWLER, RICHARD D ROWE, AND ANDREW G KOREY Division of Cardiology, Department ofPaediatrics, Hospital for Sick Children, Toronto, and Department ofPaediatrics, University of Toronto, Canada SUMMARY The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P< 01) and respiratory rate (P< 0 05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spiro- nolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure. Spironolactone, a pharmacological antagonist of the We excluded or withdrew from the study any adrenal mineralocorticoid,l has been used for some infant in whom any of the following was present copyright. years in the treatment of congestive heart failure or developed. (1) Renal disease or dysfunction, as (CHF). By competitively binding to specific nuclear shown by blood urea nitrogen >8-925 mmol/l macromolecules in the distal convoluted renal (25 mg/100ml) or hepatic disease or dysfunction.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Chlorothiazide Versus Metolazone in Hospitalized Patients with Heart
    Chlorothiazide Versus Metolazone in Hospitalized Patients with Heart Failure Receiving Loop Diruetics Barry Nicholson, PharmD; Halley Gibson, PharmD, BCPS Lahey Hospital & Medical Center, Burlington, MA Background Baseline Characteristics Secondary Outcomes Results • Heart failure (HF) is the primary diagnosis in > 1 million hospitalizations annually Characteristic Metolazone Chlorothiazide p-value • Loop diuretics are first-line treatment for edema for most patients with HF, and Secondary Outcome Metolazone Chlorothiazide p-value (n=62) (n=59) thiazide diuretics may be used as an adjuvant option for additional diuresis1 (n=62) (n=59) • Previous trials have shown that oral metolazone is non-inferior to intravenous chlorothiazide with regards to safety and efficacy2,3 Age (years) ± SD 75.6 ± 12.1 74.8 ± 12.1 0.55 Hypokalemia within 24 hours 13 (21) 14 (23.7) 0.89 • There is currently no institution-specific policy to guide thiazide diuretic post-thiazide, n (%) Male, n (%) 40 (64.5) 34 (56.7) 0.55 selection in patients with heart failure at Lahey Hospital & Medical Center Hypokalemia within 72 hours 10 (16.1) 5 (8.5) 0.32 post-thiazide, n (%) Objective Weight (kg) ± SD 92 ± 32.8 95.5 ± 31.1 0.54 To evaluate the safety and efficacy of chlorothiazide versus metolazone for Hypomagnesemia within 24 hours 5 (8.1) 7 (11.9) 0.69 Non-ICU, n (%) 48 (77.4) 39 (65) 0.24 augmented diuresis in hospitalized heart failure patients receiving loop diuretics post-thiazide, n (%) Endpoints Progressive Care Unit, n (%) 12 (19.4) 3 (5.1) 0.07 Hypomagnesemia within 72 hours 9 (14.5) 6 (10.2) 0.66 post-thiazide, n (%) Primary Endpoint Change in net urine output (UOP) pre and post-initiation Intensive Care Unit, n (%) 2 (3.2) 17 (28.8) <0.01* of either study thiazide diuretic at 24 and 72 hours Length of Stay, days ± SD 14.7 ± 6.6 17 ± 11.8 0.2 Serum creatinine, mg/dL ± SD 2.2 ± 1.2 2.2 ± 1.1 0.91 Secondary Endpoints - Incidence of the following at 24 and 72 hours: # patients needing additional 27 (43.5) 37 (62.7) 0.05 1.
    [Show full text]
  • Potassium and Magnesium-Sparing Diuretics
    Originalia Potassium and Magnesium-Sparing Diuretics M. P. Ryan Summary chez i) des rats non anesthesies avec une gebnis entspricht der unterschiedlichen Be­ charge saline ii) la clearance renale chez les handlung von Kalium und Magnesium im The renal handling of potassium and mag­ animaux anesthesies iii) des patients avec distalen Tubulus und im Sammelrohr. nesium and the effects of diuretics on these insuffisance cardiaque congestive chroni­ Auch bei Triamteren wurden magnesium­ processes are reviewed. Loop-blocking que. Dans des etudes sur I'animal, une rela­ sparende Eigenschaften nachgewiesen. Die diuretics cause major losses of both potas­ tion dose-reponse a ete etablie pour les ac­ Wirkungen von Aldosteron-Antagonisten sium and magnesium. Thiazide diuretics tions de I'amiloride dans la reduction de sind allerdings noch nicht so eingehend cause major losses of potassium while their !'excretion fractionnee du Mg et du K au nachgewiesen. effects on magnesium excretion are less well cours de la diurese induite par le furose­ established. Evidence has accumulated in mide. Les effets de l'amiloride sur !'excre­ recent years that the potassium-sparing tion du Mg sont moindres que ceux sur diuretics also exert magnesium-sparing !'excretion du K qui est compatible avec un Introduction properties. Experiments from our own traitement different de K et de Mg dans le laboratories and from other investigators tubule distal et le canal collecteur. L'triam­ Congestive heart failure is a disease are reviewed. Amiloride has been demons­ terene est I'diuretique peuvent avoir aussi trated to exert magnesium-sparing proper­ proprietes d'epargne du Mg. Lcs effets des which may be associated with dis­ ties in i) conscious saline-loaded rats ii) re­ antagonistes de I' aldosterone sur l'excretion turbances in the four main cations nal clearance studies in rats iii) congestive du Mg sont mains bien etablis que ceux de namely sodium, potassium, calcium heart failure patients.
    [Show full text]
  • Should We Switch from Bendrofluazide to Chlorthalidone As the Initial Treatment for Hypertension? a Review of the Available Medication
    ORIGINAL SCIENTIFIC PAPER SYSTEMatic REVIEW Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication Bruce Arroll MBChB, PhD, FRNZCGP; Henry Wallace Department of General Practice and Primary ABSTRACT Health Care, University of Auckland, Private Bag INTRODUCTION: Thiazide diuretics are commonly prescribed in the treatment of hypertension. 92019, Auckland 1142, However, thiazide diuretics may not all be equal in their ability to reduce cardiovascular New Zealand disease outcomes. AIM: To determine if bendroflumethiazide/bendrofluazide, the most commonly used diuretic for hypertension in New Zealand, is as effective as other diuretics in terms of cardiovascular disease outcomes. METHODS: Using recent reviews of thiazide-like (chlorthalidone or indapamide) and thiazide-type diuretics (hydrochlorothiazide and bendrofluazide) and a separate search of bendrofluazide, data on cardiovascular disease outcomes was extracted. RESULTS: Nineteen relevant papers with 21 comparisons were found. All thiazide-based diu- retics have been reported in at least one trial showing them to be more effective than placebo for cardiovascular disease outcomes, with the exception of chlorothiazide. There were no comparisons of bendrofluazide alone with other medications, but there were two studies with either bendrofluazide or hydrochlorothiazide compared withb -blockers; however, the pooled relative risk (RR) was not significant (RR = 1.10 (95% CI, 0.84–1.43)). For chlorthalidone, there were four comparisons with other medications, and the summary RR was statistically signifi- cant for cardiovascular disease outcomes (RR = 0.91 (95% CI, 0.85–0.98)). Chlorthalidone was significantly more effective for some cardiovascular disease outcomes when compared with doxazosin, amlodipine and lisinopril.
    [Show full text]